Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 9.9% a year over the last 3 years.
- It holds more cash than debt: $183.2M against $166.4M.
- It bought back its own shares for $15.3M in the last fiscal year, 3.5% of its market value.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (CAD)
Diluted EPS (CAD)
- Analyst estimate
Revenue grew by 73% a year over 5 years. Over the last 3 years it grew by 9.9% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $21.7M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 3.3 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 1
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $3.5 is 179% above today's price. 17% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
- Cannabis 100%
By region
The company reports no revenue by region.
Cannabis brings in 100% of revenue.
Segments in detail